Prelude Therapeutics (PRLD) Interest Expenses (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Interest Expenses data on file, last reported at $20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 11.66% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $20.3 million (down 11.66% YoY), and the FY2025 full-year result was $211.9 million, up 16.02% from the prior year.
• Interest Expenses climbed to $20.3 million in Q1 2026, from $734000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $111.1 million in Q4 2022 to a low of $482000.0 in Q4 2023.
• A 5-year average of $22.1 million and a median of $12.1 million in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses tumbled 99.57% in 2023 and jumped 1519.46% in 2024, its largest moves.
• Tracing PRLD's Interest Expenses over 5 years: stood at $111.1 million in 2022, then plunged by 99.57% to $482000.0 in 2023, then advanced by 10.37% to $532000.0 in 2024, then soared by 37.97% to $734000.0 in 2025, then surged by 2661.17% to $20.3 million in 2026.
• Business Quant data shows PRLD's Interest Expenses at $20.3 million in Q1 2026, $734000.0 in Q4 2025, and $21.6 million in Q3 2025.